NASDAQ OMX

UK Corporate confidence in cyber protection contrasts with lack of employee awareness of the threats

Del

Two-thirds of UK companies believe they are 'highly protected' and can adequately react to threats, but low 'cyber IQ' among employees poses a threat

LONDON, June 06, 2017 (GLOBE NEWSWIRE) -- Two-thirds (63 percent) of UK businesses believe that their organisation is highly protected from attempts by outsiders to gain access to their systems and data, according to a survey by Willis Towers Watson. A similar proportion of organisations (66 percent) maintain that they have the right processes in place to adequately react to privacy and security threats.

The findings, from Willis Towers Watson's Cyber Pulse Survey, illustrate responses from organisations and their employees on cyber security practices across the United States and United Kingdom. The survey found that a majority of companies feel that they are adequately prepared for cyberattacks on their organisations, despite the frequency and breadth of impact of cyberattacks across industries in recent years seemingly indicating the contrary.

However, the Survey also found that the disparity between corporate feelings of preparedness and the increasing number of cybersecurity incidents could be a result of lack of responsibility or accountability among employees, the human element of the cyber equation. UK employees ranked "insufficient understanding" (61 percent) as the biggest barrier to their organisation effectively managing its cyber risk. Nearly half (46 percent) spent 30 minutes or less on cybersecurity training in 2016, and over a quarter (27 percent) received none at all.

More concerning for employers is the discovery that of the employees that did complete cyber training, nearly two-thirds (62 percent) admitted they "only completed the training because it was required", and nearly half (44 percent) believe that "opening any email on their work computer is safe", suggesting that the employees may not be engaged or feel the personal accountability necessary to drive long-term, sustainable behaviours.

Anthony Dagostino, Head of Global Cyber Risk, Willis Towers Watson, said: "As the world has seen with the proliferation of phishing scams, most recently highlighted by the global WannaCry ransomware attack, the opening of just one suspicious email containing a harmful link or attachment can lead to a company-wide event. However there appears to be a disconnect between executive priorities around data protection and the need to invest in a cyber-savvy workforce through training, incentives and talent management strategies."

Willis Towers Watson's Survey also detailed additional barriers that companies feel impact their cyber preparedness and the degree to which corporations are providing cyber training to their employers. Some additional findings include:

  • Over 30 percent of employees surveyed have logged into their work-designated computer or mobile device over an unsecured public network (such as public Wi-Fi)
  • Only 40 percent of the employers surveyed felt that they had made progress addressing cybersecurity factors tied to human error and behaviours in the last three years

"Hackers are exploiting the fact that while corporations are building walls of technology around their organisations and their networks, by far the biggest threat to corporate digital security and privacy continues to come from the employees within, often completely by accident," said Dagostino. "A truly holistic cyber risk management strategy requires at its core a cyber-savvy workforce, however organisations first have to know where the vulnerabilities are in order to plug the gaps. Many organisations are facing talent deficiencies and skills shortages in their IT departments, which in turn are creating significant loopholes in their overall security measures. 

According to the Survey respondents, the costs associated with minimising cyber risk will continue to rise as technology evolves and becomes more sophisticated. This heavy emphasis on technology is crucial given the competing sophistication of cyber criminals, but it is also encouraging that human capital solutions and improvement of operating procedures will be a priority for over 70% of organisations in the next three years based on the Survey," says Dagostino. 

About Willis Towers Watson

Willis Towers Watson (NASDAQ:WLTW) is a leading global advisory, broking and solutions company that helps clients around the world turn risk into a path for growth. With roots dating to 1828, Willis Towers Watson has 40,000 employees serving more than 140 countries. We design and deliver solutions that manage risk, optimise benefits, cultivate talent, and expand the power of capital to protect and strengthen institutions and individuals. Our unique perspective allows us to see the critical intersections between talent, assets and ideas - the dynamic formula that drives business performance. Together, we unlock potential. Learn more at willistowerswatson.com.

Media contact

Jamie Kilduff: + 44 (0) 207 1703746
Jamie.kilduff@willistowerswatson.com

Claire Rumbellow: +44 (0) 207 4269433
willistowerswatson@cognitomedia.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Willis Towers Watson Public Limited Company via Globenewswire

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer18.10.2017 16:53Pressemelding

AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study. Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performanc

Nasdaq and SGX Establish Collaborative Listings Agreement18.10.2017 15:42Pressemelding

NEW YORK and SINGAPORE, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (Nasdaq:NDAQ) and Singapore Exchange (SGX) today announced the signing of a collaborative agreement in a move to leverage their strengths as two of the leading listings venues in the U.S. and Asia respectively. The new agreement seeks to enhance the channels available for companies to access capital market funding and enhance their corporate profile in both markets. As part of this agreement, Nasdaq and SGX -- who also share a successful, long-term market technology relationship -- are currently exploring the demand among corporates for a concurrent or sequential listing on both exchanges. Nasdaq and SGX are committed to supporting companies that are interested in pursuing this route. "The business landscape today is borderless," said Loh Boon Chye, CEO, SGX. "Fast-growing Asian companies looking to tap the capital markets can choose to list on SGX on Asian home ground, and embark on a listing on Nasdaq

Colliers International Expands in Washington, D.C.18.10.2017 14:30Pressemelding

Acquisition of Beltway Real Estate Services Firm Strengthens Ongoing Commitment to the Region TORONTO and WASHINGTON, Oct.  18, 2017  (GLOBE NEWSWIRE) -- Leading global commercial real estate services firm Colliers International Group Inc. (NASDAQ:CIGI)(TSX:CIGI) announced today the acquisition of leading tenant representation advisory firm Serten Advisors. With its office in Tysons Corner, the firm serves global, national, and regional clients with a highly skilled and experienced team of professionals that have more than 100 years of combined experience. "This strategic acquisition positions Colliers to gain additional market share and win new business in the vibrant and competitive Suburban DC markets," said Marty Pupil, Colliers International President | U.S. Brokerage. "Adding Steve and Paul and the rest of their talented leadership team to our existing group of professionals in the region will further position Colliers as the commercial real estate services firm of

InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC18.10.2017 14:00Pressemelding

InSphero AG / InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. New 3D InSight(TM) Human Liver Fibrosis Model represents a powerful tool for screening efficacy and safety of anti-fibrotic drugs in vitro. Schlieren, Switzerland, Oct. 18, 2017 (GLOBE NEWSWIRE) -- InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, will present data characterizing and demonstrating the utility of its new 3D InSight(TM) Human Liver Fibrosis Model for screening efficacy of anti-fibrotic drugs.  The findings will be presented at oral and poster presentations this Friday at the annual meeting of the American Association for the Study of Liver Disease (AASLD) Conference in Washington, DC.  Anti-fibrotic therapi

Kofax Wins "Most Innovative Solution for Banking Customer Authentication" Award for Third Consecutive Year18.10.2017 08:00Pressemelding

Grand Prix Banque & Innovation Honor Recognizes Kofax Mobile ID Customer Onboarding Solution and its Anti-Fraud Capabilities IRVINE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Kofax ®, a leading provider of software to simplify and transform the First Mile(TM) of business, today announced that Kofax Mobile ID(TM) has won "Most Innovative Solution for Banking Customer Authentication" in the 2017 Grand Prix Banque & Innovation Awards in Paris, France. Now in its fourth year, the Awards identify excellence and innovation in the banking sector. The program acknowledges technology companies that have launched and implemented the most outstanding banking-related software solutions, initiatives and projects in France over the past twelve months. This award highlights the new facial recognition and ID verificationfeatures of Kofax Mobile ID that determine the authenticity and validity of identification documents and their holders.  

World Conference on Lung Cancer Wednesday Press Conference: PD-1/PD-L1 Advancements and Interventions to Prevent and Treat Lung Cancer18.10.2017 06:25Pressemelding

YOKOHAMA, Japan, Oct. 18, 2017 (GLOBE NEWSWIRE) -- The final press conference from the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) highlighted new advancements surrounding the discovery of PD-1 and PD-L1, including a discussion from the researcher credited with discovering PD-1, as well as interventions to prevent lung cancer and improve quality of life for lung cancer patients. Innovations in lung cancer treatment linked to the discovery of PD-1 Prof. Tasuku Honjo of Japan, who was the first to identify PD-1 in 1992, shared an update on how PD-1 blockers have been widely used to treat many types of cancers. After decades of study, research into PD-1 has led to breakthrough immunotherapy treatments that are being hailed as a "penicillin moment" in cancer treatment. "I believe that, just as a number of antibiotics developed in the wake of the discovery of penicillin now p

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom